Sample in
A sample would enter a disposable cartridge in the intended workflow concept.
Development-stage company overview
Reproductive microfluidics, built with legal discipline
Aevrium Biosciences is a development-stage reproductive microfluidics company advancing Aevrium Select, an investigational product concept intended to explore a selected sperm fraction plus point-of-use confidence workflow for fertility laboratories.
This overview explains the problem, development plan, and intended workflow direction in a non-enabling manner, without disclosing patent-sensitive implementation details or making clinical, regulatory, or investment-performance claims.
StatusDevelopment-stage product concept
Plan12-month product-proof roadmap
ModelIllustrative consumables-led scenarios
Publication postureNo offer, no medical claim
Public legal status
Important publication and regulatory notices
This page is a general company overview for public information only. It is not an offer to sell securities, a solicitation to buy securities, medical advice, a regulatory submission, or a representation that any Aevrium product is cleared, approved, available for sale, or clinically proven.
Development-stageAevrium Select is an investigational product concept in product-proof development.
No clinical claimStatements describe intended design goals and development hypotheses, not demonstrated patient outcomes.
No securities offerFinancing references are illustrative company-planning context only; any offering would occur through formal documents.
Patent-safe disclosureTechnical details are summarized at a high level, without enabling geometry, dimensions, or operating recipes.
Aevrium Select
A development hypothesis, not a public efficacy claim.
Aevrium Select is an investigational workflow concept focused on selection, observation, scoring, and embryologist-facing confidence outputs, with further validation, usability testing, and regulatory review required before any product claims.
Select
The system is intended to explore enrichment for a better-performing sperm subpopulation.
Observe
Observation would occur in a defined region without disclosing implementation details.
Score
Analysis goals include motion, cleanliness, and recovery adequacy measures, subject to validation.
Output
The intended output is a fraction plus an interpretive confidence signal, including conservative no-call handling when evidence is insufficient.
Workflow context
A narrow development focus within a high-value IVF workflow.
The market figures below are company-planning context only. They are not revenue forecasts, clinical claims, reimbursement claims, or representations of actual adoption.
449,772U.S. IVF treatment cycles cited in the current investor deck.Used for wedge exposure sizing.
2%–5%Conservative catastrophic-failure band used for market framing.Presented as exposure, not guaranteed revenue.
$173M–$432MCompany-planning estimate of exposed patient spend.Illustrative company-planning context.
$23M–$63MCompany-planning estimate of direct lab-cost consumption.Illustrative proxy only; not additive or guaranteed.
IP and defensibility
A patent-safe story at the workflow-system level.
Aevrium describes its technology at a workflow-system level, without enabling geometry, dimensions, drawings, or operating recipes. Statements regarding intellectual property, protection, or defensibility are high-level descriptions and should not be read as legal conclusions, freedom-to-operate opinions, or guarantees of patent scope.
1
Who advances
Core selection architecture is described only at a high level as a low-shear, geometry-guided development approach.
2
Who is preserved
Validation-gated capture and path-closure concepts are described as intended system-level design goals.
3
Who is kept out
Selective exclusion is described as a non-enabling design objective without public disclosure of device-enabling details.
Fareban-linked provenance
Aevrium is a Fareban operating company. Its relationship with Fareban is described at a high level while preserving a non-enabling disclosure posture. Licensing, ownership, patent, and freedom-to-operate matters are addressed through formal diligence materials.
Disclosure-safeWhat counts as proof
Bench evidence comes first.
The product-proof program is intended to measure bench performance, handling, usability, and workflow fit before any clinical-outcome, regulatory, or commercial claims are made.
Better selection delta
Test enrichment, cleanliness, and usable recovery versus current prep logic.
Low-shear handling
Evaluate whether a gentle microenvironment can be preserved in a disposable cartridge workflow.
Objective validation
Develop practical readouts for future validation without adding dashboard complexity.
No workflow friction
Assess operator burden, chamber gentleness, recovery practicality, and ease of use as first-tier metrics.
Illustrative development plan
Twelve-month product-proof roadmap.
The roadmap is a planning framework for product-proof work. References to capital allocation, timing, and outputs are illustrative and subject to financing, technical results, partner availability, regulatory considerations, and management discretion.
Product-DNA decision workstream
Fabricate a comparator set, complete gated downselection, document a lead-architecture decision, and preserve backup options if warranted.
Head-to-head benchmark workstream
Benchmark against current prep logic, evaluate repeatability, and develop a usability package around operator simplicity, chamber gentleness, recovery practicality, and consumable-use logic.
Pilot-readiness workstream
Prepare pilot-readiness materials, partner-facing protocols, and an evidence-based summary of benchmark and usability results, subject to appropriate legal and regulatory review.
0–3 months
Build and dry-fluidic readiness
Comparator fabrication and dry-fluidic checks targeted, including priming, bubble behavior, and path stability.
4–6 months
Early biology and selection delta
Motility enrichment, carryover, and viability metrics targeted for comparison across branches.
7–9 months
Head-to-head benchmark
Lead branch targeted for testing versus current prep logic; reproducibility and usability to be scored.
10–12 months
Pilot-ready package
Partner materials, pilot protocol, and evidence summary prepared for appropriate legal and regulatory review before broader use.
Illustrative commercial scenarios
Consumables-led scenarios, not forecasts.
The examples below are illustrative company-planning scenarios for discussion only. They are not forecasts, promises, valuation support, guaranteed pricing, guaranteed adoption, or evidence of market acceptance.
$2.5M
Example only: 25 labs × 200 cycles × assumed $500 cartridge price.
$11.25M
Example only: 75 labs × 300 cycles × assumed $500 cartridge price.
$37.5M
Example only: 150 labs × 500 cycles × assumed $500 cartridge price.
Scenario figures are included to explain business-model logic only. They should not be used as revenue guidance, valuation support, or a representation that any lab will adopt, purchase, reimburse, or use the product.
Value creation
Prove the product concept first. Consider broader paths later.
Potential future paths depend on technical evidence, regulatory strategy, IP diligence, partner interest, financing, and market conditions. They should not be read as promised outcomes.
Strategic partnerships
Clinical, IVF, and workflow partners could support evaluation if measurable lab-side evidence and appropriate agreements are in place.
Platform licensing
Workflow logic and cartridge architecture may support licensing discussions after technical and legal diligence, subject to formal agreements.
Strategic acquisition
Strategic interest may become possible if evidence, IP position, regulatory path, and market conditions support it.
Risk discipline
A product-risk investment, not a leap-of-faith platform bet.
The development program is structured around explicit risks and mitigation rather than broad public claims. Any investment analysis would require formal diligence and offering materials.
Risk: technical validation
Selection performance or sensing fidelity may not reach practical relevance.
- Stage the build.
- Benchmark against current prep workflows before making performance claims.
Risk: clinical adoption
Fertility labs may resist any workflow change, especially before sufficient evidence and usability validation.
- Position as an adjunct.
- Score operator burden, recovery practicality, and usability directly.
Risk: single-point failure
A narrow technical dependency could create development risk.
- Evaluate multiple technical branches in a controlled, disclosure-safe manner.
- Preserve defensibility in cartridge workflow and validation-control layers.
Team and governance
Built for focused execution with partner leverage.
Aevrium is organized for focused execution, with additional team, advisor, clinical, and manufacturing details to be shared through appropriate company channels as they become available.
Operating company
Aevrium Biosciences
Dedicated operating focus on Aevrium Select, product-proof planning, pilot-readiness preparation, and disciplined external communications.
IP and venture provenance
Fareban-linked platform
Fareban provides strategic provenance for the Aevrium operating-company structure and technology position, subject to formal documentation and diligence.
Execution network
Clinical, engineering, and manufacturing partners
Execution planning includes fabrication, benchmark testing, usability package development, and partner-readiness preparation, subject to financing and appropriate approvals.
Investor relations
Investor inquiries begin through Aevrium’s screened diligence channel.
Investor inquiries begin by email or the optional request form below. Qualified inquiries may receive confidential materials, controlled investor documents, or private meeting options only after review. No confidential materials, technical files, financial terms, projections, diligence materials, or scheduling links are released automatically from this website.
Investor inquiries: investors@aevrium.comGeneral inquiries: inquiries@aevrium.com
Partnerships: partnerships@aevrium.com
Website: www.aevrium.com
Screened access only: Aevrium may provide confidential materials or a Calendly/private scheduling link only after initial screening. No public scheduling link or automatic materials download is displayed on this site.
Optional request form: investor materials
Use this intake form to prepare an Aevrium investor inquiry for the all-company investor inquiry system. Submitting opens an email draft to investors@aevrium.com with the routing fields needed for portfolio-level tracking. Confidential investor materials are not released automatically; Aevrium reviews each inquiry before providing diligence materials or any private scheduling option.